A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorInnovent Biologics (Suzhou) Co. Ltd.

About this trial

It is a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of recombinant Anti-IL-RAP humanized monoclonal antibody injection in subjects with acute gout flare

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Understand and sign the informed consent form;

Aged 18 to 75 years, male or female, male or female;

Body Mass Index (BMI) between 18.0 kg/m² and 40.0 kg/m²;

Meets the 2015 American College of Rheumatology (ACR) Gout Classification Criteria;

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Compound Betamenth Group

    Drug

    Intramuscular injection 2ml/bottle

  • IBI3011 GROUP

    Drug

    Subcutaneous injection 300mg/bottle

Treatment groups

132 Participants
are divided into 2 treatment groups
Group A: Compound Betamenth GroupActive comparator 1 intervention
Group B: IBI3011 GROUPExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

The change in the gout pain intensity in the target joint measured by VAS

The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. In this study patients scored their pain intensity in the joint most affected at Baseline on a 0-100 mm VAS, ranging from no pain (0mm) to unbearable pain (100mm), at 72 hours post-dose. Scores on the 100 mm linear scale were measured to the nearest millimeter from the left.

Time frame
72 hours post-dose

Secondary outcomes

1

Patients assessment of gout pain intensity in the target joints measured by VAS(0-100mm)

The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. In this study patients scored their pain intensity in the joint most affected at Baseline on a 0-100 mm VAS, ranging from no pain (0mm) to unbearable pain (100mm). Scores on the 100 mm linear scale were measured to the nearest millimeter from the left.

Time frame
up to 24 weeks
2

The change in the gout pain intensity in the target joint measured by VAS.

The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. In this study patients scored their pain intensity in the joint most affected at Baseline on a 0-100 mm VAS, ranging from no pain (0mm) to unbearable pain (100mm). Scores on the 100 mm linear scale were measured to the nearest millimeter from the left.

Time frame
up to 24 weeks
3

The number of patients with at least 1 new gout flare

Time frame
up to 24 weeks
4

Time to at Least a 50%,70% Reduction in Baseline Pain Intensity

The Visual Analog Scale (VAS) is an instrument used to measure a person's subjective quantitative evaluation of an item such as pain intensity. In this study patients scored their pain intensity in the joint most affected at Baseline on a 0-100 mm VAS, ranging from no pain (0mm) to unbearable pain (100mm). Scores on the 100 mm linear scale were measured to the nearest millimeter from the left.

Time frame
up to 120 hours

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: